| Literature DB >> 11772426 |
Abstract
Drugs that indirectly lower blood cholesterol through their actions in the gut have been used for many years. Their utility has been limited by poor tolerability, and hence, poor compliance. New resins are better tolerated and offer an advantage to older drugs. New strategies focusing on reducing serum cholesterol by acting on the gastrointestinal tract may hold even greater promise, combining the safety of nonsystemic agents with the acceptance of statins.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11772426 DOI: 10.1007/s11883-002-0065-8
Source DB: PubMed Journal: Curr Atheroscler Rep ISSN: 1523-3804 Impact factor: 5.113